RxDoctor Payments Data

Jad Khoury, MD

Infectious Disease · Saint Louis, MONPI 1144250028

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.6% of the total across 159 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Gilead at 31.3% of the total.

$2,522in general payments, 2019–2025

Across 159 payments — averaging $15.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$789
  • AbbVie$356
  • Viiv Healthcare Company$304
  • Insmed, Inc.$271
  • Merck$217
  • Shionogi Inc$149
  • plus $438 from 12 others

What the payments were for

  • Food & beverage$2,36194%
  • Education$1616%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,522 in reported general payments places this provider in the 75th percentile of 177 infectious disease providers in Missouri.

See all infectious disease providers in Missouri

Medicare billing

Part B allowed, 2024
$58,650
Medicare patients
187
Services billed
659

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala69$307,474
TriumeqAbacavir/Dolutegravir/Lamivudi32$122,780
TeflaroCeftaroline Fosamil Acetate20$65,296
GenvoyaElviteg/Cob/Emtri/Tenof Alafen12$55,436
Daptomycin64$9,519
Methenamine Hippurate73$5,889
ErtapenemErtapenem Sodium13$4,625
CeftriaxoneCeftriaxone Sodium78$4,358
Rifampin33$2,349
Doxycycline Hyclate57$1,940
Cefepime Hcl15$1,587
Cefdinir16$1,253
CefuroximeCefuroxime Axetil33$1,201
Fluconazole24$990
Ethambutol Hcl13$839

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya$789$362,91081 claims
Viiv Healthcare CompanyTriumeq$304$122,78032 claims
AbbVieTeflaro$356$65,29620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 177 infectious disease providers in Missouri.

Other infectious disease in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →